Market Introduction
The United Arab Emirates (UAE), Saudi Arabia and South Africa are the major countries in the Middle East & Africa region. Saudi Arabia was the largest market for virus-like particles in this region in 2021. The market for virus-like particles in the Middle East & Africa Saudi Arabia is anticipated to grow at higher CAGR during the forecast period; this growth is attributed to the rising prevalence of various diseases and increasing government initiatives in terms of funding and healthcare related policies.
Economic uncertainties and ongoing conflicts are worsening the condition in the region. For instance, countries like Syria, Libya, and Yemen are suffering violent conflict and cannot implement any public health measures. Iran was in a deep economic recession due to the US sanctions. Additionally, tightened financial condition is also decreasing the economic activities in the region. Many countries are facing a shortage of COVID19 vaccines in the region. Various developing developed countries in the regions are lagging for the supplies of COVID19 vaccines. Thus, it is potential for global vaccines manufacturers to explore the untapped section of Middle East Africa. For instance, as per the data published in the Brookings Institution in August 2021, the vaccination in low- and middle-income countries in the Middle East Africa was estimated at Jordan 25% and Morocco 27%, no country in Middle East Africa has been able to provide more than 15% of their populations with one dose of the vaccine. Thus, offers a potential market for the VLP related market in the region and positively impacts the VLP market in the region.
Market Overview and Dynamics
The virus-like particles market in Middle East & Africa is expected to grow from US$ 152.83 million in 2021 to US$ 249.12 million by 2028; it is estimated to grow at a CAGR of 7.2% from 2021 to 2028. Various players in the healthcare market and research organizations are actively involved in product innovations and developments. The use of virus-like particles is an emerging approach used in the biopharmaceuticals industry. As virus-like particles lack the viral content, they are easier to handle than the actual viral components. The VLPs can be used for aiding drug delivery, imaging, immunotherapy, and theragnostic. For instance, as per a study published in the NCBI in June 2020, VLP can be used in the form of nanoparticles in applications such as photothermal therapy, PET and CT imaging, MRI contrast agent carriers, optical imaging, inflammatory and autoimmune disease vaccines, cancer immunotherapy, and small molecule drug delivery (in cancer therapy). Thus, such potential applications of VLPs are expected to provide growth opportunities to market players during the forecast period.
Key Market Segments
In terms of product type, the hepatitis segment accounted for the largest share of the Middle East & Africa virus-like particles market in 2021. In terms of source, the yeast segment accounted for the largest share of the Middle East & Africa virus-like particles market in 2021. In term of application, vaccines segment held a larger market share of the virus-like particles market in 2021.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the virus-like particles market in Middle East & Africa are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Merck & Co., Inc.; GlaxoSmithKline plc.; Pfizer Inc.; Sanofi; Serum Institute of India Pvt. Ltd.; BHARAT BIOTECH; LG Chem; and VBI Vaccines Inc. among others.
Reasons to buy report
- To understand the Middle East & Africa virus-like particles market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for Middle East & Africa virus-like particles market
- Efficiently plan M&A and partnership deals in Middle East & Africa virus-like particles market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Middle East & Africa virus-like particles market
- Obtain market revenue forecast for market by various segments from 2021-2028 in Middle East & Africa region.
Middle East & Africa Virus-like Particles Market Segmentation
Middle East & Africa Virus-like Particles Market – By Product type
- Hepatitis
- Cancer/HPV
- Gaucher Disease
Middle East & Africa Virus-like Particles Market – By Source
- Yeast
- Insect Cell
- Plant
- Others
Middle East & Africa Virus-like Particles Market – By Application
- Vaccines
- Therapeutics
Middle East & Africa Virus-like Particles Market – By Country
- Saudi Arabia
- South Africa
- UAE
- Rest of MEA
Middle East & Africa Virus-like Particles Market – Companies Mentioned
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Pfizer Inc.
- Sanofi
- Serum Institute of India Pvt. Ltd.
- BHARAT BIOTECH
- LG Chem
- VBI Vaccines Inc.
Middle East and Africa Virus-like Particles Market Strategic Insights
Middle East and Africa Virus-like Particles Market Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 152.83 Million |
| Market Size by 2028 | US$ 249.12 Million |
| CAGR (2021 - 2028) | 7.2% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product Type
|
|
Regions and Countries Covered
|
|
| Middle East and Africa | South Africa, Saudi Arabia, UAE, Rest of Middle East and Africa |
| Market leaders and key company profiles |
|
Middle East and Africa Virus-like Particles Market Country and Regional Insights
